Effect of Soluble dietary fiber on NAFLD Liver Disease

A pilot study of the effects of soluble dietary fiber on liver steatosis and liver function in patients with nonalcoholic fatty liver disease (NAFLD). - SDF-NAFLD

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031220714

Enrollment

Registered

2023-03-20

Start date

2023-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease fatty liver

Interventions

soluble dietary fibrer

D065626

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: nonalcoholic fatty liver disease diagnosised by Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 and MRI-PDFF more than 3.5%

Exclusion criteria

Exclusion criteria: pregnant pateints, patients who is blest-feeding, patients who can't undergo MRI, patients allergic to this supplements

Design outcomes

Primary

Measure	Time frame
Serum ALT levels before and after the end of treatment (12 weeks later) (6 g/day group, 18 g/day group)	—

Secondary

Measure	Time frame
Serum AST before and after treatment (6 g/day group, 18 g/day group) before and after completion of treatment (12 weeks) Serum gamma-GTP before and after treatment (6 g/day group, 18 g/day group) at the end of treatment (after 12 weeks) MRI-PDFF values before and after treatment (6 g/day group and 18 g/day group) before and after the end of treatment (12 weeks) Change in stool characteristics before and after administration (6 g/day group, 18 g/day group) Comparison of ALT, AST, gamma-GTP, MRI-PDFF and stool characteristics change in different doses of SunFiber (6g/day group vs. 18g/day group)	—

Measure

Time frame

Serum AST before and after treatment (6 g/day group, 18 g/day group) before and after completion of treatment (12 weeks) Serum gamma-GTP before and after treatment (6 g/day group, 18 g/day group) at the end of treatment (after 12 weeks) MRI-PDFF values before and after treatment (6 g/day group and 18 g/day group) before and after the end of treatment (12 weeks) Change in stool characteristics before and after administration (6 g/day group, 18 g/day group) Comparison of ALT, AST, gamma-GTP, MRI-PDFF and stool characteristics change in different doses of SunFiber (6g/day group vs. 18g/day group)

—

Contacts

Public ContactMasato Yoneda

Yokohama City University Hospital

yoneda@yokohama-cu.ac.jp+81-45-787-2640

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026